Avian influenza virus H9 subtype divalent inactivated vaccine and preparation method thereof

Abstract

The invention discloses an avian influenza virus H9 subtype divalent inactivated vaccine and a preparation method thereof, and belongs to the field of vaccine preparation. The vaccine is prepared by taking an H9 subtype avian influenza virus QC strain with a preservation number of CCTCC NO: V201804 and an H9 subtype avian influenza virus WT strain with a preservation number of CCTCC NO: V201805 asantigens through inactivation. The avian influenza virus H9 subtype divalent inactivated vaccine is a double-strain vaccine and is initiated on the market. The QC strain belongs to an A antigen groupand the WT strain belongs to a B antigen group, so that the two strains have obvious antigen group representativeness and has relatively high neutralization titer for other strains in the groups. Thedouble-strain vaccine does not influence the generation of antibodies, is capable of improving the antibody titer to a certain extent and enabling the antibodies to be located in a relatively high level in a relatively long time, and has a protection rate of 100% for prevalent strains.

Description

technical field [0001] The invention belongs to the field of vaccine preparation, and in particular relates to a bivalent inactivated vaccine of avian influenza virus H9 subtype and a preparation method thereof. Background technique [0002] Since my country first reported the isolation of H9N2 subtype avian influenza virus from chickens in 1994, this subtype influenza virus has been spreading and circulating in some major poultry raising areas in my country, and has formed endemic diseases. H9 subtype avian influenza virus can cause death and drop in egg production after infecting poultry, and co-infection with other pathogens can lead to high mortality, which has caused huge economic losses to my country's poultry industry. At the same time, the H9 subtype avian influenza virus can infect humans, pigs and other mammals, which is of great significance in public health. [0003] According to the classification and analysis standards of H9 subtype avian influenza virus antig...

AI Technical Summary

Problems solved by technology

According to the results of serum cross test, chicken embryo neutralization test and challenge protection test, there are two major antigen groups, A and B, in the current popular h9.4.2.5 branch, and the antigen difference between the two antigen groups can reach 16~ 64 times; the chicken embryo neutralization test results show that there are also large differences in the neutralization titer between A and B antigen group strains, and the existing H9 subtype vaccine can no longer play a complete protective role

Images